Skip to main content

Sertraline Administration to Prevent Intradialytic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (SLATAN Study)

In brief

Sertraline cuts dialysis-related low blood pressure episodes by 40% in a small trial

In a 37-patient crossover trial, people with frequent blood pressure drops during dialysis had 2.5 episodes over four weeks on sertraline, versus 4.2 on placebo. The reduction was seen in patients with diabetes, but not those without it; symptoms and rescue interventions also fell, with similar rates of side effects. Larger, longer studies are needed to confirm the benefit.

Journal
American journal of nephrology (Q1)
Published
10 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Prit Kusirisin, Chidchanok Ruengorn, Surapon Nochaiwong, Kajohnsak Noppakun
PMID
43007857
DOI
10.1159/ajn/ablag035

Why clinicians should know about it

  • Picked for Nephrology (top studies of the week, 15 November 2026): Sertraline reduces intradialytic hypotension episodes in dialysis

Abstract

INTRODUCTION: Intradialytic hypotension (IDH) is common during hemodialysis and is associated with adverse outcomes. Although sertraline may improve autonomic dysfunction, which contributes to the pathogenesis of IDH, its efficacy in preventing IDH remains uncertain. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled, crossover trial in maintenance hemodialysis patients with IDH in ≥25% of sessions. Participants received sertraline or placebo for 4 weeks, followed by a 4-week washout before crossover (total 12 weeks). Sertraline was initiated at 50 mg/day for 1 week and increased to 100 mg/day for weeks 2-4. Primary outcome was the incidence of IDH. Secondary outcomes included IDH incidence stratified by diabetes status, symptomatic IDH, therapeutic interventions, intradialytic blood pressure changes, and adverse events. RESULTS: Thirty-seven patients were enrolled (mean age 64.0 years; 49% male; median dialysis vintage 24 months). In the intention-to-treat analysis, sertraline significantly reduced IDH episodes compared with placebo (2.5 vs 4.2 episodes per patient, p for treatment effect<0.001, period effect=0.607, sequence effect=0.577). Among diabetic patients, IDH incidence was lower with sertraline (2.5 vs 4.3 episodes per patient, p<0.001), whereas no difference was observed in non-diabetic patients. Sertraline also reduced symptomatic IDH (0.5% vs. 1.4%, p=0.036) and therapeutic interventions (5.2 vs. 8.4 events, p=0.001). Systolic blood pressure and mean arterial pressure at 1- and 3-hours during dialysis were significantly higher with sertraline. Adverse events were comparable. CONCLUSIONS: In maintenance hemodialysis patients with frequent IDH, sertraline significantly reduced IDH episodes, particularly among those with diabetes, decreased symptomatic events and rescue interventions, and improved intradialytic hemodynamic stability.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.